Posted by Michael Wonder on 16 Sep 2021
Takeda’s Exkivity (mobocertinib) approved by U.S. FDA as the first oral therapy specifically designed for patients with EGFR exon 20 insertion positive NSCLC
15 September 2021 - Next generation sequencing companion diagnostic test approved simultaneously to support identification of patients with EGFR exon 20 insertion mutations.
Takeda today announced that the U.S. FDA has approved Exkivity (mobocertinib) for the treatment of adult patients with locally advanced or metastatic non-small-cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations as detected by an FDA approved test, whose disease has progressed on or after platinum-based chemotherapy.
